PRRT (lu 177 dotatate ) treatment in india
_____________________________
Schedule Consultation
– Start Online Consultation
If you or your loved one is considering PRRT (Lu-177 Dotatate) Treatment, early evaluation is important. Fuda Cancer Centre supports patients across India. There is no need to visit the hospital initially — simply take an online consultation from home.
Our expert Dr. Anup Aboti will review your PET/CT scans, pathology reports, and medical history to determine whether PRRT Therapy is suitable for your condition. Fill out the form to schedule your online consultation today.
Start Online Consultation →PRRT (Lu-177 Dotatate) is an advanced targeted radionuclide therapy used to treat certain neuroendocrine tumours (NETs). Patients from India can receive expert evaluation through online consultation before planning treatment. This precision therapy delivers radiation directly to cancer cells while minimising damage to surrounding healthy tissues.
What Is PRRT (Lu-177 Dotatate)?
Peptide Receptor Radionuclide Therapy (PRRT) is a highly specialised cancer treatment designed for neuroendocrine tumours. It works by attaching a radioactive molecule (Lu-177) to a targeting agent that binds to tumour cells expressing somatostatin receptors.
Once administered, the therapy delivers focused radiation directly to cancer cells, helping to slow tumour growth and control symptoms.
Why PRRT Is Gaining Popularity in India
- Highly targeted cancer treatment
- Designed specifically for neuroendocrine tumours
- Minimises damage to healthy tissues
- Helps control tumour progression
- May improve symptom management
- Suitable for advanced or metastatic disease
Many patients consider PRRT when conventional treatments are no longer effective or when tumours are widespread.
Who May Benefit From PRRT
PRRT is suitable only for specific tumour types. Doctors evaluate receptor status, tumour behaviour, and overall health before recommending therapy. It may be considered for:
- Somatostatin receptor-positive tumours
- Advanced or metastatic neuroendocrine tumours
- Progressive disease despite other treatments
- Symptomatic or hormone-secreting tumours
- Patients seeking targeted treatment options
Specialised imaging scans such as PET/CT are essential for eligibility assessment.
Types of Cancer Treated With PRRT
- Gastroenteropancreatic NETs
- Pancreatic neuroendocrine tumours
- Small intestine NETs
- Lung neuroendocrine tumours
- Metastatic neuroendocrine tumours
- Recurrent NETs
Procedure Timeline & Recovery
Day of Treatment
- Intravenous infusion of therapy
- Monitoring during administration
- Short observation period
First Week
- Mild fatigue or nausea (if any)
- Return to normal activities
- Hydration and supportive care
Subsequent Cycles
- Treatment given in multiple cycles
- Periodic blood tests and imaging
- Tumour response evaluation
Recovery and response vary depending on tumour type and patient condition.
Alternative or Supportive Treatments
- Somatostatin analog therapy
- Targeted therapy
- Chemotherapy
- Surgery (selected cases)
- Symptom-directed supportive care
PRRT is often integrated into a broader treatment strategy for neuroendocrine tumours.
Treatment Comparison
| Treatment | Approach | Recovery | Targeting |
|---|---|---|---|
| PRRT (Lu-177) | Targeted radionuclide therapy | Short | Highly targeted |
| Chemotherapy | Systemic drug therapy | Variable | Broad |
| Surgery | Invasive removal | Longer | Localised |
| Radiation Therapy | External / internal | Ongoing | Moderate |
How to Choose the Right PRRT Centre
- Expertise in nuclear medicine
- Advanced PET/CT imaging facilities
- Multidisciplinary cancer team
- Comprehensive patient evaluation
- Structured follow-up care
How Indian Patients Can Get Started
Patients can share PET/CT scans, pathology reports, and medical history online for expert assessment. Doctors provide eligibility evaluation, treatment planning, and guidance before any hospital visit.
Benefits for Indian Patients
- Online consultation from home
- Highly targeted cancer therapy
- Short hospital visits
- Minimal disruption to daily life
- Personalised treatment planning
- Ongoing monitoring and support
PRRT represents a major advancement in neuroendocrine tumour treatment. Specialists design personalised therapy plans to optimise outcomes while prioritising patient safety and quality of life.
Alternatives & When They Fit Better
PRRT is a highly specialised treatment designed for specific neuroendocrine tumours. However, it is not always the first treatment choice. Doctors evaluate tumour biology, disease stage, receptor status, and patient health before deciding the best approach.
- Somatostatin Analog Therapy – Often preferred for slow-growing tumours and long-term symptom control
- Targeted Therapy – Suitable when tumours show specific molecular features
- Chemotherapy – Considered for aggressive or rapidly progressing disease
- Surgery – Best for localised tumours that can be safely removed
- Radiation Therapy – Used for local tumour control or symptom relief
PRRT is typically recommended when tumours are somatostatin receptor-positive and disease progression requires a targeted systemic therapy.
Latest Updates & What’s Changing
PRRT continues to advance with improvements in nuclear medicine technology and clinical protocols. These developments aim to enhance treatment precision and patient safety.
- More accurate PET/CT imaging for better patient selection
- Refined dosing strategies to optimise effectiveness
- Improved kidney protection techniques
- Enhanced monitoring of bone marrow function
- Better management of therapy-related side effects
Ongoing research focuses on improving long-term outcomes and identifying the most effective treatment combinations.
Key Differences: Side-by-Side
| Treatment | Main Purpose | Targeting Precision | Body Impact |
|---|---|---|---|
| PRRT (Lu-177) | Deliver radiation directly to tumour cells | Highly targeted | Focused therapeutic effect |
| Chemotherapy | Destroy rapidly dividing cells | Broad | Systemic effects |
| Targeted Therapy | Block cancer growth pathways | Moderate to high | Drug-specific effects |
| Surgery | Remove tumour mass | Localised | Invasive procedure |
Each treatment serves a distinct clinical role. Many patients receive multiple therapies during the course of their disease.
Cost & Ongoing Needs
PRRT is a complex nuclear medicine therapy requiring specialised facilities, trained experts, and strict safety protocols. Treatment costs vary depending on patient condition and institutional practices.
- Therapy is delivered in multiple cycles
- Requires specialised radioactive medication (Lu-177)
- Includes imaging and laboratory assessments
- Regular blood tests are essential
- Follow-up scans are required
- Long-term monitoring is recommended
Patients should discuss treatment planning, monitoring requirements, and financial considerations with their healthcare team.
Preparing for PRRT Treatment
Careful preparation improves both safety and treatment effectiveness. Doctors provide personalised guidance based on clinical evaluation.
- Review of PET/CT imaging and receptor studies
- Blood tests for kidney and bone marrow function
- Assessment of previous treatments
- Medication adjustments if necessary
- Hydration recommendations
- Radiation safety instructions
Understanding the preparation process helps patients feel more confident and informed.
Long-Term Outcomes and Survival Rates
Treatment outcomes vary widely depending on tumour biology, disease burden, receptor expression, and patient health. PRRT is designed to slow tumour progression and improve quality of life.
- Disease stabilisation is frequently observed
- Some patients experience tumour reduction
- Symptom improvement is common
- Response duration varies between individuals
- Long-term follow-up is essential
Doctors provide individualised expectations based on imaging findings and overall clinical assessment.
Why Choose Fuda Cancer Hospital for PRRT (Lu-177 Dotatate) Treatment?
Advanced nuclear medicine expertise, precision-targeted therapy, and structured patient support for individuals across India.
Extensive Clinical Experience in PRRT with Dedicated Indian Consultation Support
Personalised PRRT Planning Based on Receptor Imaging & Disease Behaviour
Integrated Treatment Strategies for Complex Neuroendocrine Tumours
Expert Evaluation for Advanced, Recurrent, or Metastatic Disease
Structured Monitoring & Long-Term Follow-Up Support
PRRT (Lu-177 Dotatate) Treatment
Advanced targeted radionuclide therapy designed for eligible neuroendocrine tumours (NETs), focusing on precision treatment, disease control, symptom management, and preservation of quality of life for patients across India.
What Is PRRT (Lu-177 Dotatate)?
- PRRT (Peptide Receptor Radionuclide Therapy): A highly specialised nuclear medicine treatment used for tumours that express somatostatin receptors. The therapy combines a targeting molecule with a radioactive isotope (Lu-177).
- Once administered, the treatment binds specifically to tumour cells and delivers focused radiation directly to the cancer.
- This targeted approach helps slow tumour progression while minimising exposure to surrounding healthy tissues.
- PRRT is delivered in multiple treatment cycles and requires careful clinical monitoring.
- The therapy may be integrated with other treatments depending on tumour behaviour and patient condition.
Conditions Commonly Treated with PRRT
- Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs)
- Pancreatic Neuroendocrine Tumours
- Small Intestine Neuroendocrine Tumours
- Lung Neuroendocrine Tumours
- Metastatic Neuroendocrine Tumours
- Progressive Somatostatin Receptor-Positive Tumours
- Recurrent Neuroendocrine Tumours
- Symptomatic Hormone-Secreting Tumours
Why PRRT Is Important for Patients in India
PRRT offers a valuable treatment option for patients with somatostatin receptor-positive neuroendocrine tumours, particularly when disease progression continues despite conventional therapies.
The therapy is designed to deliver radiation precisely to tumour cells, helping achieve disease stabilisation and symptom control while reducing systemic treatment burden.
PRRT is often considered for patients with advanced or metastatic disease, recurrent tumours, or those requiring a highly targeted treatment approach.
With structured monitoring and follow-up, PRRT supports long-term disease management and helps maintain patient comfort and quality of life.
Frequently Asked Questions – PRRT (Lu-177 Dotatate)
Common questions patients ask about PRRT therapy, eligibility, safety, and treatment planning
What is PRRT (Lu-177 Dotatate) treatment?
PRRT (Peptide Receptor Radionuclide Therapy) is a highly targeted nuclear medicine treatment used primarily for somatostatin receptor-positive neuroendocrine tumours (NETs). The therapy delivers focused radiation directly to tumour cells while minimising exposure to surrounding healthy tissues.
Which patients are eligible for PRRT?
PRRT is recommended for patients whose tumours show somatostatin receptor positivity on specialised imaging such as PET/CT scans. Doctors also evaluate tumour behaviour, prior treatments, kidney function, bone marrow health, and overall clinical condition before recommending therapy.
Is PRRT a chemotherapy treatment?
No. PRRT is not chemotherapy. It is a targeted radionuclide therapy designed to deliver radiation directly to tumour cells. Unlike conventional chemotherapy, PRRT works through receptor-based targeting rather than affecting all rapidly dividing cells.
How is PRRT treatment administered?
PRRT is administered through an intravenous infusion. The therapy is usually delivered in multiple treatment cycles, spaced several weeks apart. Patients are monitored carefully during and after each cycle.
What are the possible side effects of PRRT?
Most patients tolerate PRRT well. Some individuals may experience temporary fatigue, mild nausea, or changes in blood parameters. Kidney function and bone marrow health are monitored closely to ensure treatment safety.
How many PRRT cycles are required?
The number of cycles varies depending on tumour response, clinical protocols, and patient condition. Doctors determine the treatment schedule based on imaging results, laboratory tests, and overall therapeutic goals.
Can PRRT be combined with other treatments?
Yes. PRRT may be integrated with Somatostatin Analog Therapy, targeted therapy, chemotherapy, or supportive care strategies depending on tumour behaviour and disease progression.
Is PRRT suitable for advanced or metastatic tumours?
PRRT is commonly considered for advanced or metastatic neuroendocrine tumours that express somatostatin receptors, especially when disease progression occurs despite conventional treatments.
How can patients begin PRRT evaluation?
Patients can begin with an online consultation by sharing PET/CT scans, pathology reports, and previous treatment records. Specialists review the case carefully and provide personalised guidance before any treatment planning.
Our Specialties & Procedures
Explore our range of advanced cancer care procedures designed to provide comprehensive treatment and improve your well-being.
Advanced Therapies For Cancer
Innovative and precise cancer treatments combining advanced technology, targeted therapy, and personalized medicine for better recovery outcomes.
Explore More →
Treating Specific Cancer
Specialized treatment plans for different cancer types — including liver, lung, breast, and bone cancers — with a focus on patient comfort and long-term wellness.
Explore More →Our Specialties & Procedures
Explore our range of advanced cancer care procedures designed to provide comprehensive treatment and improve your well-being.
Advanced Therapies For Cancer
Innovative and precise cancer treatments combining advanced technology, targeted therapy, and personalized medicine for better recovery outcomes.
Explore More →
Treating Specific Cancer
Specialized treatment plans for different cancer types — including liver, lung, breast, and bone cancers — with a focus on patient comfort and long-term wellness.
Explore More →ABOUT FUDA CANCER HOSPITAL
OUR ACHIEVEMENTS
Achievements of FUDA CANCER HOSPITAL
50+ Doctors
Professional Experts
1200+ Patients
Happy Indian Patients
100+ Countries
Global Presence
500+ Employees
Dedicated Workforce
Advanced Therapies for Cancer of All Stages
Nano Knife IRE (Irreversible Electroporation)
Cryotherapy | Cryosurgery | Cryo-ablation
Brachytherapy for Cancer
Microvascular Interventional Chemotherapy
Patient Testimonials
Mrs. Pratibha Rajgopal
Mrs. Dipikabehan Parmar
Mrs. Roseline Chandran
Mrs. Jyoti Bhatia